Background
==========

Appropriate fluid supply is a cornerstone of critical care. In addition to cardiac output CO, transpulmonary thermodilution (TPTD) provides extravascular lung water (EVLW) reflecting pulmonary edema and the preload parameter global end-diastolic volume (GEDV) \[[@B1]-[@B6]\]. Increased EVLW is associated to mortality \[[@B3],[@B7]-[@B11]\]. GEDV and its changes are associated to CO \[[@B6]\] and algorithms based on GEDV have been shown to improve outcome \[[@B12]\]. Moreover, the relation of EVLW and pulmonary blood volume (PBV) might be useful to differentiate the etiology of pulmonary edema \[[@B13],[@B14]\]. PBV can be determined using double-indicator TPTD technique \[[@B13]\]. Single indicator TPTD is much more common in clinical routine and estimates PBV as about 25% of GEDV \[[@B14]\]. EVLW/PBV-ratio has been termed pulmonary vascular permeability index "PVPI". Several studies demonstrated that higher values of PVPI are associated to pulmonary edema with increased permeability of the alveolo-capillary barrier \[[@B14]\]. Increased PVPI has been found in patients with ARDS resulting from pulmonary (e.g. pneumonia) or secondary (e.g. sepsis) pulmonary impairment. By contrast hydrostatic pulmonary edema due to congestive heart failure usually does not result in marked increases of PVPI since EVLW and PBV are increased to a similar extent \[[@B13],[@B14]\].

Although TPTD has become part of clinical routine, several pitfalls have to be kept in mind. Two recent studies demonstrated marked overestimation of GEDV in case of performing TPTD indicator injection using a femoral venous access due to the additional volume of vena cava inferior (VCI) participating in TPTD \[[@B15],[@B16]\]; Figure [1](#F1){ref-type="fig"}).

![**Comparison of transpulmonary indicator dilution (TPTD) using femoral central venous catheter (CVC) instead of jugular or subclavian CVC.** Obviously, the distribution volume for the indicator is augmented by the volume of vena cava inferior in case of femoral indicator injection. This results in diminished indicator concentration and overestimation of global enddiastolic volume GEDV. In single indicator dilution technique GEDV is calculated as difference of the total dilution volume (intrathoracic thermovolume ITTV) minus the sum of pulmonary blood volume PBV and extravascular lung water EVLW: GEDV = ITTV- (EVLW + PBV). The sum (PBV + EVLW) is thermed pulmonary thermovolume PTV, which is directly derived from the thermodilution curve. Therefore, it can be assumed not to be altered by the additional dilution volume of VCI participating in TPTD.](1471-2253-14-81-1){#F1}

The authors suggested a correction formula for GEDV indexed to predicted body surface area (GEDVI) based on data derived from femoral TPTD and biometric information. As a consequence of these data one the manufacturer of the PiCCO device (Pulsion Medical Systems, Feldkirchen, Germany) implemented a new software requiring the information about CVC site (femoral or jugular/subclavian) and correcting GEDVI in case of femoral injection. Although jugular and subclavian vein access might be the preferred sites for CVC insertion, several recent studies on catheter related bloodstream infections have demonstrated that femoral venous access was used in about 20 to 35% of all catheter insertions \[[@B17],[@B18]\]. Therefore, results of TPTD might be substantially altered in about one third of cases without appropriate correction.

To the best of our knowledge there are no data available if the new PiCCO algorithm also corrects unindexed GEDV and PVPI in case of femoral CVC.

Furthermore, data on PVPI were not investigated in both previous papers on TPTD using a femoral CVC \[[@B15],[@B16]\].

Therefore, it was the aim of our study to investigate if in case of femoral indicator injection

GEDV in the new PiCCO algorithm is given based on the correction of GEDVI and

PVPI is based on corrected GEDV and corrected pulmonary blood volume.

Methods
=======

The study was approved by the institutional review board (Ethikkommission der Fakultät für Medizin der Technischen Universität München, Munich, Germany).

All patients or their legal representatives gave written informed consent.

We prospectively performed 110 TPTDs in 11 patients with femoral indicator injection. All patients were recruited between October 2013 and January 2014.

Ten triplicate TPTDs per patient were performed with 15 mL cold saline within a total of 30 h. TPTD was performed as described previously using the PiCCO-2 device (Pulsion Medical Systems, Feldkirchen, Germany) \[[@B6],[@B16],[@B19]\] and a 5-lumen CVC (Multicath 5; Vygon; Aachen, Germany). All PiCCO-2 devices were equipped with the V3.1 algorithm requiring information about the venous catheter site which was set to "femoral" CVC in all patients.

Immediately after triplicate TPTD absolute and indexed mean values were documented for GEDV, GEDVI, EVLW, EVLWI and PVPI as displayed by the device. Parameters displayed by the device were subscripted with "displayed" (see Table [1](#T1){ref-type="table"}).

###### 

Terminology of thermodilution-derived parameters

  **Subscript**                                                                **Meaning**                                                                                                                                                                                               **Parameters analyzed**
  ---------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------
  "displayed"                                                                  Values as displayed by the PiCCO monitor                                                                                                                                                                  GEDVI~displayed~
  GEDV~displayed~                                                                                                                                                                                                                                                                        
  EVLW~displayed~                                                                                                                                                                                                                                                                        
  PVPI~displayed~                                                                                                                                                                                                                                                                        
  "calculated"                                                                 Parameters calculated based on parameters displayed on the monitor.                                                                                                                                       GEDV~calculated~
  These parameters should be consistent with corresponding displayed values.   PVPI~calculated~                                                                                                                                                                                          
  "corrected"                                                                  Parameters derived from correction of the displayed values. Corrected parameters were used for comparison to calculated values (only used in case of inconsistency of displayed and calculated values).   PVPI~corrected~
  GEDV~uncorrected~                                                                                                                                                                                                                                                                      

The main purpose of the study was to investigate the consistency of displayed values by comparing displayed data (e.g. GEDV~displayed~, PVPI~displayed~) to the corresponding values derived from calculation specified with the subscript "calculated" (GEDV~caculated~, PVPI~calculated~).

If displayed and calculated values were inconsistent, we investigated whether the inconsistency could be explained by (non-) application of the recently suggested correction formula for the displayed values parameters \[[@B16]\]. In this case "ex post" correction by our formula should result in a consistency of the "corrected" values (with the subscript "corrected") and the calculated values.

To analyze if the femoral TPTD correction formula for GEDVI~displayed~ was only applied for GEDVI~displayed~ or if also GEDV~displayed~ is corrected in case of femoral indicator injection, we calculated GEDV~calculated~ using the formula:

$${GEDV}_{calculated}\  = \ {GEDVI}_{displayed}*{BSA}_{predicted}\text{.}$$

Finally, GEDV~displayed~ was compared to GEDV~calculated~.

In a second step we analyzed, if PVPI~displayed~ is calculated based on a GEDV~displayed~ corrected for femoral indicator injection. Therefore, we compared PVPI~displayed~ to PVPI~calculated~ using the formula PVPI~calculated~ = EVLW~displayed~/(0.25 \* GEDV~displayed~).

Predicted bodyweight BW~predicted~ was calculated using the formula:

$$\begin{array}{l}
{{Predicted}\ {bodyweight}\ {BW}_{predicted}\left\lbrack {kg} \right\rbrack:\ {Male}:\ 50\  + \ 0.91\ *\ \left( {{height}\ –\ 152.4} \right)} \\
{{Female}:\ 45.5\  + \ 0.91\ *\ \left( {{height}\ –\ 152.4} \right)} \\
\end{array}$$

Predicted body surface area BSA~predicted~ was calculated using BW~predicted~ instead of actual bodyweight in the Dubois formula:

$${BSA}_{Dubois}\left\lbrack m^{2} \right\rbrack\  = \ 0.007184*{weight}\ \left\lbrack {kg} \right\rbrack^{0.425}*{height}\ \left\lbrack {cm} \right\rbrack^{0.725}$$

The correction formula suggested for correction of uncorrected femoral indicator injection derived GEDV~uncorrected~ is GEDVI~corrected~ \[mL / m^2^\] = 0.539 \* GEDVI~uncorrected~ - 15.17 + 24.49 \* CI~uncorrected~ +2.311\* BW~ideal~\[[@B16]\].

Ideal bodyweight BW~ideal~ was calculated using the formula:

$$\begin{array}{l}
{{Ideal}\ {bodyweightBW}_{ideal}\left\lbrack {kg} \right\rbrack:\ {Male}:\ \left( {{height}\ –\ 100} \right)\ x\ 0.9} \\
{{Female}:\ \left( {{height}\ –\ 100} \right)\ x\ 0.85} \\
\end{array}$$

Correlation of GEDV~calculated~ and GEDVI~displayed~ was analyzed using Spearman correlation. Comparisons of GEDV~displayed~ vs. GEDV~calculated~, PVPI~displayed~ vs. PVPI~calculated~ and PVPI~corrected~ vs. PVPI~calculated~ were performed using Wilcoxon-test for paired samples, respectively. Bland-Altman analyses and calculation of percentage error (PE) were used for these comparisons as described previously \[[@B20],[@B21]\]. Bland-Altman analyses were corrected for repeated measurements allowing variability of true values within each subject \[[@B22]\].

All analyses were performed using IBM SPSS Statistics 21 (SPSS inc., Chicago, IL, USA).

Results
=======

Patients characteristics
------------------------

Five female and six male patients were included. Patients characteristics are shown in Table [2](#T2){ref-type="table"}.

###### 

Patients characteristics (mean ± standard deviation; numbers and percentages)

  **Gender**                                   **5/11 (45%) female; 6/11 (55%)male**
  ------------------------------------------- ---------------------------------------
  Age \[years\]                                             59.9 ± 11.9
  Height \[cm\]                                            171.1 ± 11.7
  APACHE-II score                                             16 ± 6
  SOFA score                                                 6.5 ± 2.5
  Actual bodyweight \[kg\]                                  72.8 ± 19.1
  Predicted bodyweight \[kg\]                               65.0 ± 12.0
  Ideal bodyweight \[kg\]                                   62.5 ± 11.4
  Predicted body surface area \[m^2^\]                      1.76 ± 0.22
  Aetiology                                                       
     Sepsis                                                 7/11 (64%)
     ARDS                                                    1/11 (9%)
     Cirrhosis                                               1/11 (9%)
     Cardiogenic shock                                      2/11 (18%)
  Measurements under mechanical ventilation               60/110 (54.5%)
  Measurements under vasopressors                         34/110 (30.9%)

GEDV~calculated~ was obtained by multiplying GEDVI~displayed~ by BSA~predicted~. As demonstrated in Figure [2](#F2){ref-type="fig"} GEDV~calculated~ and GEDV~displayed~ significantly correlated (r^2^ = 1.0; p \< 0.001) and were not significantly different (1459 ± 365 mL vs. 1459 ± 366 mL).

![**Scatter plot depicting the correlation of GEDV as displayed by the PiCCO-2 device (GEDV**~**displayed**~**) vs. GEDV calculated as product GEDVI**~**displayed**~**\* predicted body surface area.**](1471-2253-14-81-2){#F2}

This confirms that correction for femoral venous catheter site pertains to both GEDVI~displayed~ and GEDV~displayed~.

Consequently, calculation of PVPI~calculated~ based on EVLW~displayed~ and GEDV~displayed~ should result in a PVPI~calculated~ identical with PVPI~displayed~.

However, PVPI~displayed~ was significantly lower than PVPI~calculated~ (Figure [3](#F3){ref-type="fig"}; 1.64 ± 0.57 vs. 2.27 ± 0.72; p \< 0.001).In addition to a bias of -0.64 ± 0.22 Bland-Altman analysis demonstrated a percentage error of 22% and upper and lower limits of agreement of -0.199 and -1.075 (Figure [4](#F4){ref-type="fig"}).

![**Boxplots plots comparing pulmonary vascular permeability index PVPI as displayed by the PiCCO-2 device (PVPI**~**displayed**~**) vs. PVPI calculated as ratio of EVLW/PBV (extravascular lung water/pulmonary blood volume) vs. PVPI corrected using the formula suggested for correction of femoral indicator injection derived GEDV**\[[@B16]\]**: GEDVI**~**corrected**~**\[mL / m**^**2**^**\] = 0.539 \* GEDVI**~**uncorrected**~**- 15.17 + 24.49 \* CI**~**uncorrected**~**2.311\* BW**~**ideal**~**.** Assuming that PVPI~displayed~ was calculated based on GEDV and PBV not corrected for femoral injection, PVPI~corrected~ was calculated by multiplying PVPI~displayed~ with the ratio 0.25\*GEDV~uncorrected~/0.25\*GEDV~corrected~.](1471-2253-14-81-3){#F3}

![**Bland Altman plot comparing pulmonary vascular permeability index PVPI as displayed by the PiCCO-2 device (PVPI**~**displayed**~**) vs. PVPI calculated as ratio of EVLW/PBV (extravascular lung water/pulmonary blood volume).**](1471-2253-14-81-4){#F4}

This could be explained if instead of the corrected GEDV~displayed~ an uncorrected GEDV~uncorrected~ was used for calculation of PBV and PVPI~displayed~.

Based on this hypothesis and also assuming that the formula for femoral indicator injection suggested by our group is used by the latest PiCCO algorithm we determined PVPI~corrected~ by multiplying PVPI~calculated~ by the ratio GEDV~uncorrected~/GEDV~displayed~.

As shown in Figure [5](#F5){ref-type="fig"} the bias of PVPI~displayed.d~ to EVLW/PBV could be reduced from -0.64 ± 0.22 to -0.10 ± 0.05. Furthermore, percentage error decreased from 22% to 4% with upper and lower limits of agreement of -0.009 and -0.190 (Figure [5](#F5){ref-type="fig"}).

![**Bland Altman plot comparing pulmonary vascular permeability index PVPI**~**displayed**~**corrected by the correction formula for femoral indicator injection (PVPI**~**corrected**~**; see Figure**[3](#F3){ref-type="fig"}**) vs. PVPI calculated as ratio of EVLW/PBV (extravascular lung water/pulmonary blood volume).**](1471-2253-14-81-5){#F5}

Discussion
==========

Despite improving outcome by a number of specific and unspecific approaches such as low tidal volume \[[@B23]\], extracorporeal lung assist \[[@B24]\] and prone positioning \[[@B25]\] ARDS still carries a high mortality of up to 65% \[[@B23]-[@B26]\]. Well balanced fluid management providing appropriate resuscitation \[[@B27]\] as well as avoiding fluid overload-particularly of the lungs-is another obvious approach to improve outcome in ARDS. EVLW has been validated as a significant predictor of outcome in ARDS \[[@B3],[@B7]-[@B11]\]. However, with regard to fluid management it is important, if increased EVLW derives from inflammatory capillary leakage of the lungs or from general fluid overload and congestive heart failure. Relating EVLW to pulmonary blood volume, PVPI has been demonstrated to discriminate inflammatory from congestive pulmonary failure \[[@B13],[@B14]\]. Therefore, combined use of EVLW and PVPI has been suggested to specify therapy in acute pulmonary failure. However, there are a number of studies suggesting pitfalls in using these parameters derived from TPTD: Due to its current indexation solely to bodyweight EVLWI might be inappropriately lowered in obese patients. Therefore, weight correction formulas \[[@B19]\] and indexation of EVLWI to height \[[@B19],[@B28]\] have been shown to improve usefulness of EVLWI. Furthermore, femoral central vein access for TPTD indicator injection inappropriately increases GEDV(I) \[[@B15],[@B16]\]. Therefore, a correction formula for GEDVI in case of femoral CVC has been suggested \[[@B16]\]. Requirement of information about the CVC site in the last PiCCO algorithm suggests that some kind of correction for femoral CVC is provided. Due to the assumption that PBV is 25% of GEDV in single indicator TPTD \[[@B6],[@B12]\], overestimation of GEDV in femoral indicator TPTD indicator injection also pertains to PVPI.

However, no information is available,

-- if correction provided by the new PiCCO-algorithm applies only to GEDVI or also to GEDV

-- if this correction is similar to the formula suggested by Saugel et al. \[[@B16]\] and

-- if PVPI~displayed~ is based on PBV and GEDV derived from the correction formula suggested by our group.Therefore, we performed a prospective study in patients with femoral CVC access showing the following main results that are graphically summarized in Figure [6](#F6){ref-type="fig"}.

![**Algorithm for the calculation of GEDV, GEDVI, PBV and PVPI as displayed by the PiCCO-2 software V 3.1 (PVPI**~**displayed**~**) and as suggested using GEDV**~**corrected**~**and PBV**~**corrected**~**for the calculation of PVPI**~**calculated**~**.** Values not displayed are shaded.](1471-2253-14-81-6){#F6}

GEDV~displayed~ is corrected to the same degree as GEDVI~displayed~.

However, PVPI~displayed~ provided by the PiCCO-device is significantly lower than PVPI~calculated~ derived by dividing EVLW~displayed~ by 0.25\*GEDV~displayed~. This suggests the use of uncorrected GEDV and uncorrected PBV for the PVPI displayed by the device.

This assumption is supported by PVPI~corrected~ values nearly identical to PVPI~calculated~ when correcting PVPI~displayed~ using the correction formula.

Practical implications
----------------------

Our data strongly suggest that the correction formula for GEDVI in case of femoral CVC indicator injection should be also applied for the calculation of PVPI. Otherwise, PVPI would remain to be artificially lowered in case of femoral CVC which also would result in different PVPI threshold for inflammatory vs. congestive pulmonary impairment.

Limitations of the study
------------------------

Despite conclusive results with high statistical significance this is a single centre study with a limited number of patients and TPTD measurements. Furthermore, we have to admit that our explanations for this inconsistency are in part speculative: Although correction of PVPI~displayed~ by our formula results in PVPI~corrected~ close to PVPI~displayed~, the hypothesis of a "neglect" of correction of PBV has to be proven by a confirmatory study. Future studies should verify the practical implications, e.g. showing improved association of PVPI with outcome when applying the correction formula also for PBV and PVPI. Furthermore, our findings could be confirmed by comparing PVPI derived from femoral and jugular indicator injection in patients with both femoral and jugular CVC.

Finally, these findings pertain to the PiCCO-2 device with the V3.1 algorithm. To the best of our knowledge, there is only one other device providing PVPI which is the Edwards EV 1000 VolumeView (Edwards Lifesciences; Irvine, CA, USA). Despite some minor modifications of the thermodilution analysis this device is comparable to the PiCCO. However, the EV-1000 does not require information about the CVC site. This suggests that the device does neither correct GEDV(I) nor PVPI in case of femoral CVC site.

Conclusion
==========

This study suggests that the V3.1 software of the PiCCO-device corrects GEDVI and GEDV for TPTD indicator injection based on a correction formula similar to the correction recently suggested \[[@B16]\]. However, correction of GEDV(I) does not pertain to PVPI which is contradictory to the definition of PVPI and results in a substantial underestimation of PVPI. To make PVPI values derived from jugular and femoral indicator injection comparable, corrected GEDV and PBV should be used for calculation of PVPI in case of femoral CVC.
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